Controlling blood uric acid after pancreatic cancer surgery to improve survival
Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
This analysis will see if changes in blood uric acid after pancreatic cancer surgery relate to survival for people who had their tumor removed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 168 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Hepatopancreatobiliary Surgery Institute of Gansu Province Academic / other |
| Locations | 1 site (Lanzhou, Gansu) |
| Trial ID | NCT07091526 on ClinicalTrials.gov |
What this trial studies
This is a retrospective observational analysis of patients with pathologically confirmed primary pancreatic cancer who underwent radical resection (pancreaticoduodenectomy or distal pancreatectomy) at a single center in Lanzhou, Gansu. Investigators will extract preoperative and postoperative serum uric acid (SUA) measurements from medical records and correlate changes in SUA with overall survival and postoperative outcomes, using available clinical data to adjust for confounders. Patients with conditions or treatments that substantially affect uric acid (for example gout, chronic kidney disease, or long-term urate-lowering therapy) are excluded to reduce bias. The study aims to determine whether perioperative changes in SUA can serve as a prognostic marker after pancreatic cancer resection.
Who should consider this trial
Good fit: Adults with pathologically confirmed primary pancreatic cancer who underwent radical resection (pancreaticoduodenectomy or distal pancreatectomy), have available pre- and postoperative uric acid measurements, and survived at least six weeks after surgery are the intended population.
Not a fit: Patients with preexisting gout, chronic kidney disease, use of long-term urate-lowering drugs, recent dialysis or plasma exchange, certain metabolic or hematologic disorders, nonpancreatic primary tumors, pregnant or postpartum women, or those lacking follow-up data are unlikely to benefit from these findings.
Why it matters
Potential benefit: If successful, tracking postoperative uric acid changes could help identify patients at higher risk of poor survival and guide closer follow-up or targeted interventions.
How similar studies have performed: Some observational work has linked higher serum uric acid to worse outcomes in hepatobiliary cancers, but using postoperative change in SUA as a prognostic marker specifically for pancreatic cancer is novel and not yet established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with pathologically confirmed pancreatic cancer (primary) * Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy） * The postoperative survival time was at least 6 weeks Exclusion Criteria: * No surgery was performed, or only palliative surgery/ biopsy was performed * Patients who underwent emergency hemodialysis or plasma exchange after surgery * History of gout or long-term urate-lowering therapy, such as allopurinol * Patients are missing follow-up data * Hydrochlorothiazide and furosemide were used * Chronic kidney disease * Oncolytic syndrome * Hemolytic anemia * Lead poisoning * Hyperparathyroidism * Hypothyroidism * A tyrosinase inhibitor was used * Patients with nonpancreatic primary tumors * Pregnant or postpartum women.
Where this trial is running
Lanzhou, Gansu
- Hepatopancreatobiliary Surgery Institute of Gansu Province — Lanzhou, Gansu, China (Recruiting)
Study contacts
- Principal investigator: Wenbo Meng, M.D. Ph. D. — Hepatopancreatobiliary Surgery Institute of Gansu Province
- Study coordinator: Wenbo Meng, M.D. Ph. D.
- Email: mengwb@163.com
- Phone: 13919177177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.